Gamez Mauricio E, Patel Samir H, McGee Lisa A, Sio Terence T, McDonald Mark, Phan Jack, Ma Daniel J, Foote Robert L, Rwigema Jean-Claude M
Radiation Oncology, The Ohio State University - The James Cancer Center, Columbus, OH, USA.
Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA.
Int J Part Ther. 2021 Jun 25;8(1):131-154. doi: 10.14338/IJPT-20-00064.1. eCollection 2021 Summer.
To evaluate the clinical outcomes and treatment related toxicities of charged particle-based re-irradiation (reRT; protons and carbon ions) for the definitive management of recurrent or second primary skull base and head and neck tumors.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were applied for the conduct of this systematic review. Published work in English language evaluating the role of definitive charged particle therapies in the clinical setting of reRT for recurrent or second primary skull base and head and neck tumors were eligible for this analysis.
A total of 26 original studies (15 protons, 10 carbon ions, and 1 helium/neon studies) involving a total of 1,118 patients (437 with protons, 670 with carbon ions, and 11 with helium/neon) treated with curative-intent charged particle reRT were included in this systematic review. All studies were retrospective in nature, and the majority of them (n=23, 88 %) were reported as single institution experiences (87% for protons, and 90% for carbon ion-based studies). The median proton therapy reRT dose was 64.5 Gy (RBE 1.1) (range, 50.0 - 75.6 Gy ), while the median carbon ion reRT dose was 53.8 Gy (RBE 2.5 - 3.0) (range, 44.8 - 60 Gy ). Induction and/or concurrent chemotherapy was administered to 232 (53%) of the patients that received a course of proton reRT, and 122 (18%) for carbon ion reRT patients. ReRT with protons achieved 2-year local control rates ranging from 50% to 86%, and 41% to 92% for carbon ion reRT. The 2-year overall survival rates for proton and carbon ion reRT ranged from 33% to 80%, and 50% to 86% respectively. Late ≥ G3 toxicities ranged from 0% to 37%, with brain necrosis, ototoxicity, visual deficits, and bleeding as the most common complications. Grade 5 toxicities for all treated patients occurred in 1.4% (n= 16/1118) with fatal bleeding as the leading cause.
Based on current data, curative intent skull base and head and neck reRT with charged particle radiotherapy is feasible and safe in well-selected cases, associated with comparable or potentially improved local control and toxicity rates compared to historical reRT studies using photon radiotherapy. Prospective multi-institutional studies reporting oncologic outcomes, toxicity, and dosimetric treatment planning data are warranted to further validate these findings and to improve the understanding of the clinical benefits of charged particle radiotherapy in the reRT setting.
评估基于带电粒子的再程放疗(reRT;质子和碳离子)用于复发性或第二原发性颅底及头颈部肿瘤确定性治疗的临床疗效和治疗相关毒性。
本系统评价采用系统评价和Meta分析的首选报告项目(PRISMA)指南。评估确定性带电粒子疗法在复发性或第二原发性颅底及头颈部肿瘤再程放疗临床环境中作用的英文发表作品符合本分析要求。
本系统评价纳入了26项原始研究(15项质子治疗、10项碳离子治疗和1项氦/氖治疗研究),共1118例接受根治性意图带电粒子再程放疗的患者(437例接受质子治疗,670例接受碳离子治疗,11例接受氦/氖治疗)。所有研究本质上均为回顾性研究,其中大多数(n = 23,88%)报告为单机构经验(质子治疗为87%,碳离子治疗研究为90%)。质子治疗再程放疗的中位剂量为64.5 Gy(生物效应剂量1.1)(范围50.0 - 75.6 Gy),而碳离子再程放疗的中位剂量为53.8 Gy(生物效应剂量2.5 - 3.0)(范围44.8 - 60 Gy)。232例(53%)接受质子再程放疗疗程的患者以及122例(18%)碳离子再程放疗患者接受了诱导和/或同步化疗。质子再程放疗的2年局部控制率为50%至86%,碳离子再程放疗为41%至92%。质子和碳离子再程放疗的2年总生存率分别为33%至80%和50%至86%。晚期≥3级毒性发生率为0%至37%,脑坏死、耳毒性、视觉障碍和出血是最常见并发症。所有接受治疗患者的5级毒性发生率为1.4%(n = 16/1118),致命出血是主要原因。
基于现有数据,在精心挑选的病例中,采用带电粒子放疗进行根治性意图的颅底及头颈部再程放疗是可行且安全的,与使用光子放疗的既往再程放疗研究相比,局部控制率和毒性发生率相当或可能有所改善。需要开展前瞻性多机构研究,报告肿瘤学结局、毒性和剂量学治疗计划数据,以进一步验证这些发现,并增进对带电粒子放疗在再程放疗环境中临床益处的理解。